CA
NZ
UK
AU
IND
US
The beat reflects progress in commercializing MYQORZO and the infusion of capital from a recent equity offering, both of which are key to the company’s near‑term financial trajectory.
This slight earnings shortfall occurred as the biopharmaceutical company marked its first full quarter of commercial sales for AVLAYAH (tividenofusp alfa-eknm), generating $3.6 million in net product revenue for the Hunter syndrome treatment. This initial AVLAYAH revenue, coupled with strategic financial moves, positions Denali …
Share price moved modestly higher, reflecting market optimism about the upcoming readouts.
Health Catalyst, Inc. (NASDAQ: HCAT) has repaid its debt after selling its Vitalware business for $147 million. The company used the proceeds from the sale, along with cash on hand, to repay its outstanding debt. This move is expected to improve the company's financial …
BioLife Solutions (NASDAQ: BLFS) delivered Q2 earnings per share of $0.04, surpassing the $0.03 consensus figure, while revenue climbed 21% to $28.5 million. GAAP net income surged to $45.1 million, buoyed by a $42.4 million non‑cash tax benefit, and adjusted EBITDA hit $7.4 million, …
Concentra Group Holdings Parent, Inc. (NYSE: CON) posted second‑quarter earnings per share of $0.52, eclipsing the $0.42 consensus estimate, while revenue climbed 10.0% to $606.0 million. Net income surged 45.7% to $67.3 million, and Adjusted EBITDA rose 22.5% to $140.9 million. Investors gain confidence …
Definium Therapeutics (NASDAQ: DFTX) posted a quarterly earnings per share of $-1.44, sharply missing the $-0.56 consensus estimate, while its cash, cash equivalents and investments climbed to approximately $1.1 billion, more than double the $411.6 million balance at the end of 2025. The cash …
Eli Lilly's second-quarter revenue surged 48% year over year, reaching $23 billion, driven by booming sales of obesity treatments like Mounjaro and Zepbound. This performance prompted the company to raise its full-year revenue guidance to between $85 billion and $87 billion, indicating strong growth …
Guardian Pharmacy Services (NYSE: GRDN) posted earnings per share of $0.29 for the quarter ended June 30, comfortably beating the $0.28 consensus. Investors see the beat as a sign that the company’s growth engine remains intact while it broadens its geographic reach.
Inogen Inc (NASDAQ: INGN) achieved $95.1 million in revenue for the second quarter ending June 30, 2026, marking a 3% increase from $92.3 million during the same period last year. This growth comes as the company's earnings per share aligned positively, reporting at $-0.14 …
Please wait processing your request...